Association of spironolactone use with risk of cancer

JAMABommareddy K, Hamade H, Lopez-Olivo MA, et al. | February 11, 2022


Treatment with spironolactone does not seem to be linked with a meaningful increase in risk of cancer occurrence.

  • In this systematic review and meta-analysis of 7 observational studies, the pooled occurrence of malignancies, in particular breast and prostate cancers, was determined among those who ever used spironolactone.

  • As per observations, spironolactone use was not linked with statistically significant elevated risks of breast or other solid organ cancers.

  • It was also found to be linked with a reduced risk of prostate cancer.

Read the full article on JAMA